In a groundbreaking development for ophthalmology, the U.S. Food and Drug Administration has approved ENCELTO, a small eye implant designed to treat macular telangiectasia type 2 (MacTel), a rare neurodegenerative retinal disease that gradually erodes central vision. This marks the first FDA-authorized therapy for the condition, offering new hope to thousands affected by the disorder.
The approval follows compelling results from a Phase 3 clinical trial led by scientists at Scripps Research and the National Institutes of Health, with funding from Neurotech Pharmaceuticals. The implant works by delivering neuroprotective agents directly to the retina, helping preserve vision in patients who previously had no treatment options.
MacTel primarily affects the macula—the part of the retina responsible for sharp, central vision—and has long been considered untreatable. ENCELTO’s success signals a major shift in how retinal diseases may be managed in the future.
“One of the corresponding authors, Professor Martin Friedlander from Scripps Research, states, ‘This marks progress in changing our perception of vision loss.’ ‘Rather than waiting for cells to perish, we are discovering ways to safeguard and maintain them.'”
With FDA approval now secured, ENCELTO is expected to become a transformative option for patients and a catalyst for further innovation in retinal therapies.
